Curcumin is not a primary senolytic in the BCL-2 family inhibition sense, but its potent NF-κB inhibition directly suppresses SASP production from existing senescent cells. Additionally, curcumin activates autophagy (mTOR inhibition + Beclin-1 upregulation) and shows BCL-2 modulation at concentrations achievable with high-bioavailability formulations.

Can curcumin replace quercetin in a senolytic protocol?

No. Curcumin's SASP suppression is complementary but cannot substitute for quercetin's direct BCL-2 inhibition (senolytic mechanism). Curcumin is an excellent daily anti-SASP supplement alongside a quercetin + fisetin senolytic protocol.

What curcumin form is best for senolytic purposes?

High-bioavailability forms that achieve plasma concentrations closest to the BCL-2 modulation range: BCM-95, Longvida, NovaSol (reported 185x improvement), or Meriva phytosome. Standard powder/extract is inadequate.